Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of tislelizumab with intraperitoneal and intravenous nab-paclitaxel plus S-1 for gastric cancer with peritoneal metastasis
ChiCTR2300078838Phase 2Recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, paclitaxel and tegafur in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Cancer Center of Guangzhou Medical University. Primary endpoint: median overall survival. Started Dec 2023; status: recruiting.
02
Drugs
tislelizumabpaclitaxeltegafur
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300078838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078838.